论文部分内容阅读
在今年的美国国会山峰会上,有研究者提出,逆转1型糖尿病的关键可能有2个步骤,包括用一种药物诱导免疫耐受,用另一种药物促进胰岛再生。已经获得美国食品药品监督管理局(FDA)批准的这两类药物中的两个,将可能首次联手逆转1型糖尿病,该研究有望在今年年底开展。参与该会议的都是糖尿病界的知名人物,如美国威明顿市CureDM首席卫生官员Claresa Levetan博士、圣巴巴拉市Sansum糖尿病研究所主任Lois Jovanovic博士、罗马生物医学大学Paolo Pozzilli博士、佛罗里达大学卓越糖尿病中心顾问Desmond Schatz
At this year’s summit of the US Capitol, some researchers have suggested that the key to reversing type 1 diabetes may be two-step process, which involves using one drug to induce immune tolerance and using another drug to promote islet regeneration. Two of these two types of drugs, already approved by the U.S. Food and Drug Administration (FDA), will likely be the first to reverse type 1 diabetes, and the study is expected to begin by the end of this year. Participants at the conference are well-known figures in the diabetes community such as Dr. Claresa Levetan, Chief Health Officer, CureDM, Wilmington, USA; Dr. Lois Jovanovic, Director, Sansum Diabetes Institute, Santa Barbara; Dr. Paolo Pozzilli, University of Florida Biomedical Excellence; Desmond Schatz, Consultant, Diabetes Center